Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Jeffrey Poulton Sells 2,242 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Jeffrey Poulton sold 2,242 shares of the business’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the sale, the executive vice president owned 59,802 shares of the company’s stock, valued at approximately $18,543,404.16. The trade was a 3.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $332.61 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The stock has a market capitalization of $43.94 billion, a price-to-earnings ratio of 194.51 and a beta of 0.35. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The stock’s fifty day moving average is $371.01 and its two-hundred day moving average is $424.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.61). The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm’s revenue was up 84.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.65) earnings per share. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ALNY shares. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, January 15th. Needham & Company LLC cut their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Morgan Stanley decreased their price objective on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a report on Friday, January 30th. Stifel Nicolaus upped their target price on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Finally, Jefferies Financial Group lowered their price target on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a report on Thursday, October 30th. Twenty-two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ALNY. Groupama Asset Managment lifted its position in Alnylam Pharmaceuticals by 160.4% in the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after acquiring an additional 2,483,697 shares in the last quarter. Norges Bank bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $895,816,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Alnylam Pharmaceuticals by 698.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after purchasing an additional 1,185,909 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $369,943,000. Finally, Holocene Advisors LP bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $194,616,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $429 and reaffirmed a “buy” rating, citing upside vs. the current price (Canaccord’s note implies meaningful upside). Canaccord price-target raise
• Positive Sentiment: A MarketBeat-linked Motley Fool piece reports a pundit upgrade that helped lift sentiment and trading interest in ALNY. Why Alnylam Was Soaring
• Positive Sentiment: A bullish roundup in The Globe and Mail highlighted Alnylam among favorable healthcare ideas, supporting broader analyst-driven positivity. Analysts Are Bullish
• Neutral Sentiment: Short-interest data in the feed shows zero/NaN values and a 0.0 days-to-cover figure — likely a data/reporting artifact rather than new market pressure; treat as non-actionable until confirmed by an exchange report.
• Negative Sentiment: Multiple insider sales disclosed this week could weigh on sentiment: CEO Yvonne Greenstreet sold 6,958 shares at ~$310; several EVPs (Jeffrey Poulton, Kevin Fitzgerald, Tolga Tanguler, Pushkal Garg) sold mid‑hundreds to low‑thousands of shares at ~$310–332. These trades reduced insiders’ stakes by mid-single-digit percentages. Filings: SEC links for the disclosures. Yvonne Greenstreet SEC filing Jeffrey Poulton SEC filing Kevin Fitzgerald filings Tolga Tanguler SEC filing Pushkal Garg SEC filing
• Negative Sentiment: Chardan Capital trimmed its price target to $425 (from a higher prior target), a modest negative datapoint that partly offsets other analyst optimism. Chardan target cut

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.